Abstract

Emerging evidence suggests that the vaginal microbiota play a role in HPV persistence and cervical neoplasia development and progression. Here we examine a broad range of immune checkpoint proteins in the cervicovaginal microenvironment across cervical carcinogenesis and explore relationships among these key immunoregulatory proteins, the microbiota composition, and genital inflammation. First, we demonstrate that immune checkpoint molecules can be measured in cervicovaginal lavages. Secondly, we identify CD40, CD27, and TIM-3 to specifically discriminate cervical cancer from other groups and CD40, CD28, and TLR2 to positively correlate to genital inflammation. Finally, PD-L1 and LAG-3 levels negatively, whereas TLR2 positively correlate to health-associated Lactobacillus dominance. Overall, our study identifies immune checkpoint signatures associated with cervical neoplasm and illuminates the multifaceted microbiota-host immunity network in the local microenvironment. This study provides a foundation for future mechanistic studies and highlights the utility of cervicovaginal lavage profiling for predicting and monitoring response to cancer therapy.

Highlights

  • Cervical cancer is the most common human papillomavirus (HPV)related cancer and the fourth most common cancer in women worldwide with estimated 570,000 new cases and 311,000 deaths in 20181

  • To investigate immune checkpoint protein profiles in the local cervicovaginal microenvironment, we measured levels of 16 immune checkpoint proteins in CVL samples collected from women across cervical carcinogenesis

  • When analyzing principal components separately, PC2, but not PC1, significantly varied between the invasive cervical carcinoma (ICC) group when compared with all of the other groups (P ranging between 0.01 and

Read more

Summary

Introduction

Cervical cancer is the most common human papillomavirus (HPV)related cancer and the fourth most common cancer in women worldwide with estimated 570,000 new cases and 311,000 deaths in 20181. In lower income countries, the majority of women are diagnosed with advanced or metastatic carcinoma, which contributes to high mortality related to cervical cancer[1]. The American Cancer Society estimates 13,170 new cases of cervical cancer cases and 4250 deaths in the United States in 20193. The majority of these new cervical cancer cases occurred among women who had never or rarely been screened. The HPV vaccination coverage in the United States remains drastically lower (43% in 2017) compared with other recommended childhood vaccinations [e.g., 91% for measles, mumps, and rubella vaccine]5

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call